ANGPTL3 and homozygous familial hypercholesterolemia: However, in an African American woman with HoFH who received a combination of atorvastatin, ezetimibe, PCSK9i (alirocumab), and evinacumab, a novel monoclonal antibody against angiopoietin-like 3 (ANGPTL3), LDL-C decreased to < 1.81 mmol/L30.